Please login to the form below
CRPC
This page shows the latest CRPC news and features for those working in and with pharma, biotech and healthcare.
Exelixis bounces back with new prostate cancer data
The COSMIC-021 trial evaluated the combination treatment in patients with locally advanced or metastatic castration-resistant prostate cancer (CRPC), whose disease had progressed on prior novel hormone therapy. ... Exelixis intends to file the
Latest news
-
Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer
First approval could give Clovis an opportunity to build familiarity with its brand among clinicians treating CRPC before its big pharma rivals reach the market, although its rivals are hot on ... the first half of 2020, while GSK/J&J have also reported
-
Pfizer raises forecast following growth of biopharma business
For Pfizer, the potential approval in this indication could help drive Xtandi's growth even further – the drug picked up an approval in castration-resistant prostate cancer (CRPC) with non-metastatic ... CRPC last year.
-
J&J puts pressure on rivals with new Erleada okay in prostate cancer
Meanwhile, Zytiga – which is only approved for metastatic CRPC – pulled in $3.5bn last year, but the start of generic competition in late 2018 was evident in a 21% slump in
-
Trial backs role for Lynparza in second-line prostate cancer
subpopulation of HRRms – namely BRCA1/BRCA2 and ATM mutations – and that makes PROfound “the only positive phase 3 trial of any PARP inhibitor” in CRPC. ... AZ is also conducting a phase 3 trial (PROPEL) of Lynparza in combination with Zytiga as
-
Bayer bags FDA nod for early prostate cancer drug darolutamide
The FDA approved darolutamide under the Nubeqa brand name for men with non-metastatic CRPC, which is shaping up to be a hotly-contested category in prostate cancer. ... It is estimated that around 73, 000 men in the US will be diagnosed with
More from news
Approximately 1 fully matching, plus 41 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
In patients with non-metastatic CRPC, there is a high unmet need to delay development of metastases and the progression to advanced prostate cancer. ... for approval in the US and EU for non-metastatic CRPC on the strength of MFS data from the PROSPER
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Novavax gets $1.6bn from US government for coronavirus vaccine
- Communiqué Awards 2020: Results - Communiqué Awards
- FDA approves Roche’s Actemra COVID-19 trial
- Communiqué Awards 2020: Results - Communiqué Awards
- Mesoblast expands compassionate use COVID-19 programme
- Regeneron’s COVID-19 antibody cocktail enters phase 3 trial
- Intelligence that redefines success
- IFPMA launches AMR Action Fund to tackle antimicrobial resistance
- Merck expands partnership with Zymeworks for multispecific antibodies
- Novartis reveals full phase 3 results for Enerzair Breezhaler
- Artificial Intelligence in Digital Therapeutics
- CHECKLIST 04: Let’s make your patient recruitment strategies a success
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- CHECKLIST 04: Let’s make your patient recruitment strategies a success
- From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
- Multichannel engagement and the need for greater understanding of European markets
- By Laurence Olding and Georgina James...
- A snapshot of… Exscientia
- ...
Quick links
Infographics
